Chest
EditorialsPulmonary Hypertension Trials: Current End Points Are Flawed, But What Are the Alternatives?
References (13)
The current treatment of pulmonary arterial hypertension: time to redefine success
Chest
(2006)- et al.
Cardiopulmonary exercise testing and six-minute walk correlations in pulmonary arterial hypertension
Am J Cardiol
(2006) - et al.
Intravascular ultrasound assessment of pulmonary vascular disease in patients with pulmonary hypertension
Chest
(2001) - et al.
A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST)
Am Heart J
(1997) ACCP evidence-based guidelines for pulmonary arterial hypertension
Chest
(2004)- et al.
The endurance shuttle walking test: a responsive measure in pulmonary rehabilitation for COPD patients
Chron Respir Dis
(2006)
Cited by (16)
Incremental shuttle walk test distance and autonomic dysfunction predict survival in pulmonary arterial hypertension
2017, Journal of Heart and Lung TransplantationPrognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials
2011, Journal of Heart and Lung TransplantationCitation Excerpt :In addition, threshold values in our study were determined based on the distribution of the data, not by ROC curves. Due to inherent limitations in the 6MWD27,28 and differences in patient etiologies and their ability to perform timed tests, the lack of exercise improvement is more important than a precise inflection point by which distance walked correlates with survival. It appears that patients who walk <380 m have a poor likelihood of long-term survival, and our study implies that clinicians possibly should use an inflection point closer to 300 m in clinical practice.
Surrogate End Points in Pulmonary Arterial Hypertension: Assessing the Response to Therapy
2007, Clinics in Chest MedicineEpidemiology of Pulmonary Arterial Hypertension
2007, Clinics in Chest MedicineCitation Excerpt :They may also lead to improvements in the care of patients who have other forms of PH. Expanding therapeutic options might also allow consideration of end points beyond physical function and survival, such as health-related quality of life, when planning care [182–187]. Indeed, the continued suitability of measurements currently used to assess improvement is debated, as is the appropriate duration of these studies [188,189]. Together, these advances in therapy and the end points used to study them will continue to change our assessment of the epidemiology of PAH.
Dr. Roberts has no conflicts of interest. Drs. Preston and Hill have received honoraria from and Dr. Hill has served as a consultant for Actelion, Inc, Encysive, Cotherix, and Pfizer, Inc. Dr. Hill has received research grants from Actelion, Encysive, Cotherix, ICOS, Myogen, United Therapeutics, and Pfizer, Inc.
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/misc/reprints.shtml).